Literature DB >> 9575177

Inositol 1,3,4,5-tetrakisphosphate binding activities of neuronal and non-neuronal synaptotagmins. Identification of conserved amino acid substitutions that abolish inositol 1,3,4,5-tetrakisphosphate binding to synaptotagmins III, V, and X.

K Ibata1, M Fukuda, K Mikoshiba.   

Abstract

Synaptotagmins I and II are essential for Ca2+-regulated exocytosis of synaptic vesicles from neurons, probably serving as Ca2+ sensors. This Ca2+-sensing function is thought to be disrupted by binding of an inositol 1,3,4,5-tetrakisphosphate (IP4) to the C2B domain of synaptotagmin I or II (Fukuda, M., Moreira, J. E., Lewis, F. M. T., Sugimori, M., Niinobe, M., Mikoshiba, K., and Llinás, R. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 10708-10712). Recently, several synaptotagmin isoforms, expressed outside the nervous system, have been identified in rats and proposed to be involved in constitutive vesicle traffic. To test whether the inositol high polyphosphates also regulate constitutive vesicle traffic by binding to the non-neuronal synaptotagmins, we examined the IP4 binding properties of the recombinant C2 domains of both neuronal (III, V, X, and XI) and non-neuronal (VI-VIII and IX) synaptotagmins. The C2B domains of synaptotagmins VII-IX and XI had strong IP4 binding activity, but the C2B domain of synaptotagmin VI showed very weak IP4 binding activity. In contrast, there was no significant IP4 binding activity of the C2B domains of synaptotagmins III, V, and X or any of the C2A domains. A phylogenetic tree of the C2 domains of 11 isoforms revealed that synaptotagmins III, V, VI, and X (IP4-insensitive or very weak IP4-binding isoforms) belong to the same branch. Based on the sequence comparison between the IP4-sensitive and -insensitive isoforms, we performed site-directed mutagenesis of synaptotagmin III and identified several amino acid substitutions that abolish IP4 binding activity. Our data suggest that the inositol high polyphosphates might also regulate constitutive vesicle traffic via binding to the IP4-sensitive non-neuronal synaptotagmins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9575177     DOI: 10.1074/jbc.273.20.12267

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  The N-terminal cysteine cluster is essential for membrane targeting of B/K protein.

Authors:  M Fukuda; K Mikoshiba
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

2.  Interfacial membrane docking of cytosolic phospholipase A2 C2 domain using electrostatic potential-modulated spin relaxation magnetic resonance.

Authors:  A Ball; R Nielsen; M H Gelb; B H Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

3.  Role of the conserved WHXL motif in the C terminus of synaptotagmin in synaptic vesicle docking.

Authors:  M Fukuda; J E Moreira; V Liu; M Sugimori; K Mikoshiba; R R Llinás
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

4.  The C2A domain of synaptotagmin-like protein 3 (Slp3) is an atypical calcium-dependent phospholipid-binding machine: comparison with the C2A domain of synaptotagmin I.

Authors:  Mitsunori Fukuda
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

5.  Plasticity and adaptation of Ca2+ signaling and Ca2+-dependent exocytosis in SERCA2(+/-) mice.

Authors:  X S Zhao; D M Shin; L H Liu; G E Shull; S Muallem
Journal:  EMBO J       Date:  2001-06-01       Impact factor: 11.598

6.  Characterization of KIAA1427 protein as an atypical synaptotagmin (Syt XIII).

Authors:  M Fukuda; K Mikoshiba
Journal:  Biochem J       Date:  2001-03-01       Impact factor: 3.857

7.  A regulatory role for Src homology 2 domain-containing inositol 5'-phosphatase (SHIP) in phagocytosis mediated by Fc gamma receptors and complement receptor 3 (alpha(M)beta(2); CD11b/CD18).

Authors:  D Cox; B M Dale; M Kashiwada; C D Helgason; S Greenberg
Journal:  J Exp Med       Date:  2001-01-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.